Onward Med NV (ONWRF)

$5.60 +0.38 (7.28%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 180
Avg Vol 1,648
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 44%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company engages in developing ARCEX, a technology to enhance hand strength and sensation for individuals with SCI; ARCIM, a spinal cord stimulation system designed to address blood pressure instability and other symptoms in people with SCI; ARCBCI, an implanted brain-computer interface to restore thought-driven movement. It operates...

Industry: Biotechnology
Sector: Healthcare
Address:
Schimmelt 2, Eindhoven, Netherlands
Struin
Struin Nov. 27 at 5:09 PM
$ONWRF And part two: The company is small and therefore not yet on the radar of many American investors, but the fundamentals are now rock solid: a commercial product, FDA and EU approvals, and a platform that is clinically and technologically advanced. And I'm not even mentioning the 350 patents and the other ongoing trials for Parkinson's and stroke, mind-controlled trials, etc. If ONWARD shows continued adoption in the US in Q1, as is already evident in Q3, then the current share price is disproportionate to its future value. It's pure undervaluation, with catalysts that are only just beginning to materialize.
1 · Reply
Struin
Struin Nov. 27 at 5:09 PM
$ONWRF Very interesting post in The Netherlands, unknown gem: Part one: ONWARD Medical is at a tipping point, and the market doesn't seem to recognize it yet. Expectations are high, and everything points to the company finally showing its potential in Q1. The current valuation completely understates the position ONWARD has now achieved. • FDA approval for ARC-EX (also for home use in the US) • CE marking for Europe (clinical and home use) • First European sales already this quarter • Empower BP trial starting (blood instability in spinal cord injury) • Small population studies have already shown convincing evidence of efficacy • No competition for either ARC-EX or the future ARC-IM BP therapy CEO Dave Marver openly talks about a potential billion-dollar market – and considering the data and regulatory status, this isn't pie in the sky.
0 · Reply
Lauvier4
Lauvier4 Nov. 26 at 4:21 PM
$ONWRF $TMC $OMEX
0 · Reply
Lauvier4
Lauvier4 Nov. 26 at 4:19 PM
$ONWRF
0 · Reply
Struin
Struin Nov. 26 at 3:52 PM
$ONWRF Look at the company and all the PT's up to $12. Only up now!
0 · Reply
Struin
Struin Nov. 24 at 1:41 PM
$MLTX I have placed all my money in MLTX and ONWRF, two great companies coming months and more..... $ONWRF In the United States, the ARC-EX system is the first and only FDA-cleared technology that demonstrably improves hand strength and blood pressure stability in people with spinal cord injuries. In Europe, the first commercial sales of the ARC-EX system are expected in the fourth quarter.
0 · Reply
Struin
Struin Nov. 24 at 1:35 PM
$MLTX Look at this small Dutch company , totally unknown but a fast grower in the USA it's final FDA approved: $ONWRF Home use opens a multi-billion dollar market for Onward Medical (ABM FN-Dow Jones) The approval of Onward Medical's ARC-EX system for home use in the United States opens the door to a multi-billion dollar market of approximately 100,000 patients, a significant portion of whom will be eligible for reimbursement starting early next year. Onward Medical CEO Dave Marver told ABM Financial News on Monday.
0 · Reply
Struin
Struin Nov. 24 at 1:34 PM
$ONWRF Home use opens a multi-billion dollar market for Onward Medical (ABM FN-Dow Jones) The approval of Onward Medical's ARC-EX system for home use in the United States opens the door to a multi-billion dollar market of approximately 100,000 patients, a significant portion of whom will be eligible for reimbursement starting early next year. Onward Medical CEO Dave Marver told ABM Financial News on Monday.
0 · Reply
Struin
Struin Nov. 24 at 12:21 PM
$ONWRF In the United States, the ARC-EX system is the first and only FDA-cleared technology that demonstrably improves hand strength and blood pressure stability in people with spinal cord injuries. In Europe, the first commercial sales of the ARC-EX system are expected in the fourth quarter.
0 · Reply
Struin
Struin Nov. 24 at 11:40 AM
$ONWRF PT's Onward: Buy Degroof Petercam euro 12,30, Buy Kepler Cheuvreux euro 9,70. Updates will follow soon.
0 · Reply
Latest News on ONWRF
No data available.
Struin
Struin Nov. 27 at 5:09 PM
$ONWRF And part two: The company is small and therefore not yet on the radar of many American investors, but the fundamentals are now rock solid: a commercial product, FDA and EU approvals, and a platform that is clinically and technologically advanced. And I'm not even mentioning the 350 patents and the other ongoing trials for Parkinson's and stroke, mind-controlled trials, etc. If ONWARD shows continued adoption in the US in Q1, as is already evident in Q3, then the current share price is disproportionate to its future value. It's pure undervaluation, with catalysts that are only just beginning to materialize.
1 · Reply
Struin
Struin Nov. 27 at 5:09 PM
$ONWRF Very interesting post in The Netherlands, unknown gem: Part one: ONWARD Medical is at a tipping point, and the market doesn't seem to recognize it yet. Expectations are high, and everything points to the company finally showing its potential in Q1. The current valuation completely understates the position ONWARD has now achieved. • FDA approval for ARC-EX (also for home use in the US) • CE marking for Europe (clinical and home use) • First European sales already this quarter • Empower BP trial starting (blood instability in spinal cord injury) • Small population studies have already shown convincing evidence of efficacy • No competition for either ARC-EX or the future ARC-IM BP therapy CEO Dave Marver openly talks about a potential billion-dollar market – and considering the data and regulatory status, this isn't pie in the sky.
0 · Reply
Lauvier4
Lauvier4 Nov. 26 at 4:21 PM
$ONWRF $TMC $OMEX
0 · Reply
Lauvier4
Lauvier4 Nov. 26 at 4:19 PM
$ONWRF
0 · Reply
Struin
Struin Nov. 26 at 3:52 PM
$ONWRF Look at the company and all the PT's up to $12. Only up now!
0 · Reply
Struin
Struin Nov. 24 at 1:41 PM
$MLTX I have placed all my money in MLTX and ONWRF, two great companies coming months and more..... $ONWRF In the United States, the ARC-EX system is the first and only FDA-cleared technology that demonstrably improves hand strength and blood pressure stability in people with spinal cord injuries. In Europe, the first commercial sales of the ARC-EX system are expected in the fourth quarter.
0 · Reply
Struin
Struin Nov. 24 at 1:35 PM
$MLTX Look at this small Dutch company , totally unknown but a fast grower in the USA it's final FDA approved: $ONWRF Home use opens a multi-billion dollar market for Onward Medical (ABM FN-Dow Jones) The approval of Onward Medical's ARC-EX system for home use in the United States opens the door to a multi-billion dollar market of approximately 100,000 patients, a significant portion of whom will be eligible for reimbursement starting early next year. Onward Medical CEO Dave Marver told ABM Financial News on Monday.
0 · Reply
Struin
Struin Nov. 24 at 1:34 PM
$ONWRF Home use opens a multi-billion dollar market for Onward Medical (ABM FN-Dow Jones) The approval of Onward Medical's ARC-EX system for home use in the United States opens the door to a multi-billion dollar market of approximately 100,000 patients, a significant portion of whom will be eligible for reimbursement starting early next year. Onward Medical CEO Dave Marver told ABM Financial News on Monday.
0 · Reply
Struin
Struin Nov. 24 at 12:21 PM
$ONWRF In the United States, the ARC-EX system is the first and only FDA-cleared technology that demonstrably improves hand strength and blood pressure stability in people with spinal cord injuries. In Europe, the first commercial sales of the ARC-EX system are expected in the fourth quarter.
0 · Reply
Struin
Struin Nov. 24 at 11:40 AM
$ONWRF PT's Onward: Buy Degroof Petercam euro 12,30, Buy Kepler Cheuvreux euro 9,70. Updates will follow soon.
0 · Reply
Struin
Struin Nov. 24 at 11:25 AM
$ONWRF This with approval FDA an $10 stock
0 · Reply
Geburtstagskind
Geburtstagskind Nov. 14 at 4:05 PM
$ONWRF groundbreaking and leading Technology for SCI Patients and 24 followers on stocktwits - shame on you 🤷🏼‍♂️
1 · Reply
Geburtstagskind
Geburtstagskind Oct. 25 at 7:28 PM
$ONWRF Ottobock bought more shares in Last offering.
0 · Reply
Lauvier4
Lauvier4 Oct. 13 at 9:01 AM
$ONWRF on the moment of writing this info up 8,88%
1 · Reply
Phaethon7
Phaethon7 Oct. 13 at 7:57 AM
$ONWRF steady flow of cash https://www.nasdaq.com/articles/onward-medical-posts-preliminary-q3-revenue-over-eur-1-mln
0 · Reply
Lauvier4
Lauvier4 Oct. 8 at 12:39 PM
$ONWRF Onward up 6 % today on initial coverage by Paribas.
0 · Reply
Lauvier4
Lauvier4 Sep. 18 at 7:02 AM
$ONWRF Concurrent Publications in Nature and Nature Medicine Highlight Advances in Blood Pressure Regulation after Spinal Cord Injury Using ONWARD ARC-IM Therapy • Detailed results from clinical feasibility studies show immediate improvement in blood pressure stability and durable reduction of hypotensive symptoms, resulting in improved quality of life • Most people living with spinal cord injury experience blood pressure instability, which representsa key unmet need • Today’s concurrent publications provide clinical evidence for ARC-IM® Therapy ahead of the Company’s planned initiation of the Empower BP global pivotal trial later this year
0 · Reply
Lauvier4
Lauvier4 Jul. 1 at 7:54 AM
$ONWRF
0 · Reply
YoloAlfred
YoloAlfred Jun. 21 at 2:33 AM
$ONWRF 🤔🤔🤔🤔🤔🤔🤔🤔🤔
0 · Reply
Lauvier4
Lauvier4 May. 18 at 7:44 AM
$ONWRF OTCmarket under ONWRY
0 · Reply
Geburtstagskind
Geburtstagskind Mar. 12 at 8:04 PM
$ONWRF new in Parkinson treatment, with Support of Michael J. Fox
0 · Reply
Herrfranz
Herrfranz Jan. 23 at 7:59 PM
$ONWRF tomorrow new year high?
0 · Reply